Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 May;112(1):81–86. doi: 10.1111/j.1476-5381.1994.tb13033.x

Binding kinetics and antiplatelet activities of picotamide, a thromboxane A2 receptor antagonist.

P A Modesti 1, I Cecioni 1, A Colella 1, A Costoli 1, R Paniccia 1, G G Neri Serneri 1
PMCID: PMC1910277  PMID: 8032666

Abstract

1. Picotamide was shown to inhibit platelet binding of thromboxane A2 (TxA2)-mimetics and to cause a reduction of TxA2 platelet receptors after in vivo administration. The present study aimed to investigate directly [3H]-picotamide binding to human platelets and in particular the relationship between binding kinetics and antiaggregating properties. 2. [3H]-picotamide time-dependently bound to a single class of platelet TxA2 receptors with a KD of 325 nmol l-1 at equilibrium. The binding was displaceable by TxA2 analogues U46619 and ONO11120 (Ki 19 and 28 nmol l-1 respectively) but not by prostacyclin (PGI2), prostaglandin E2 (PGE2) and TxB2. Antiaggregating activity and TxA2 formation inhibition paralleled with binding kinetics. 3. By prolonging the incubation time from 30 to 120 min, picotamide showed a progressively increasing non-displaceable binding, whereas specific displaceable binding decreased in comparison to the values reached at 30 min. Non displaceable binding was specific, temperature-dependent saturable and followed a Michaelis-Menten kinetic (Vmaxapp = 130 fmol per 10(8) platelets h-1, KMapp = 330 nmol l-1). Picotamide progressively underwent a specific stable interaction with its platelet receptor. 4. In conclusion, after an initial reversible binding, a progressive stabilization of picotamide binding takes place resulting in a progressively more stable interaction with platelets.

Full text

PDF
81

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berrettini M., De Cunto M., Parise P., Grasselli S., Nenci G. G. "In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets. Eur J Clin Pharmacol. 1990;39(5):495–500. doi: 10.1007/BF00280943. [DOI] [PubMed] [Google Scholar]
  2. Cattaneo M., Tenconi P. M., Lecchi A., Mannucci P. M. In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production. Thromb Res. 1991 Jun 15;62(6):717–724. doi: 10.1016/0049-3848(91)90375-7. [DOI] [PubMed] [Google Scholar]
  3. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  4. Cornish-Bowden A., Eisenthal R. Estimation of Michaelis constant and maximum velocity from the direct linear plot. Biochim Biophys Acta. 1978 Mar 14;523(1):268–272. doi: 10.1016/0005-2744(78)90030-x. [DOI] [PubMed] [Google Scholar]
  5. Dorn G. W., 2nd Mechanism for homologous downregulation of thromboxane A2 receptors in cultured human chronic myelogenous leukemia (K562) cells. J Pharmacol Exp Ther. 1991 Oct;259(1):228–234. [PubMed] [Google Scholar]
  6. Modesti P. A., Abbate R., Gensini G. F., Colella A., Serneri G. G. Kinetic analysis of a TxA2 receptor antagonist. Evidence for the existence of an uptake system. Eicosanoids. 1990;3(3):139–143. [PubMed] [Google Scholar]
  7. Modesti P. A., Colella A., Abbate R., Gensini G., Neri Serneri G. Competitive inhibition of platelet thromboxane A2 receptor binding by picotamide. Eur J Pharmacol. 1989 Oct 4;169(1):85–93. doi: 10.1016/0014-2999(89)90820-0. [DOI] [PubMed] [Google Scholar]
  8. Modesti P. A., Colella A., Cecioni I., Gensini G. F., Abbate R., Neri Serneri G. G. Acute reduction of TxA2 platelet binding sites after in vivo administration of a TxA2 receptor inhibitor. Br J Clin Pharmacol. 1991 Apr;31(4):439–443. doi: 10.1111/j.1365-2125.1991.tb05560.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Narumiya S., Okuma M., Ushikubi F. Binding of a radioiodinated 13-azapinane thromboxane antagonist to platelets: correlation with antiaggregatory activity in different species. Br J Pharmacol. 1986 Jun;88(2):323–331. doi: 10.1111/j.1476-5381.1986.tb10208.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Violi F., Ghiselli A., Iuliano L., Praticò D., Alessandri C., Balsano F. Inhibition by picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol. 1988;33(6):599–602. doi: 10.1007/BF00542494. [DOI] [PubMed] [Google Scholar]
  11. Weiland G. A., Molinoff P. B. Quantitative analysis of drug-receptor interactions: I. Determination of kinetic and equilibrium properties. Life Sci. 1981 Jul 27;29(4):313–330. doi: 10.1016/0024-3205(81)90324-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES